A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Key facts
- Where
- Albuquerque, Atlantis, Baltimore, Bellaire, Dallas, Dunwoody, Escondido, Fountain Valley, Greenville, Honolulu, Hyattsville, Lake Charles, Las Vegas, Lawrenceville, Miami, Monroe, Mt. Dora, Mt. Pleasant, Nashville, Norfolk, Palm Springs, Pembroke Pines, Pensacola, Quincy, Rochester, Rolling Hills Estates, Sacramento, San Antonio, Santa Ana, Scottsdale, St. Petersburg, Stockbridge, Topeka, Troy, Tuscaloosa, Tustin, Uniontown, Warren Township, Waterbury, and West Des Moines, United StatesSee the 41 sites
- Phase
- Phase 3
Where in United States
- Albuquerque Clinical Trials, Inc.Albuquerque, United StatesTaking people
- JEM Research InstituteAtlantis, United StatesTaking people
- MedStar Good Samaritan HospitalBaltimore, United StatesTaking people
- The University of Texas Health Science Center at HoustonBellaire, United StatesTaking people
- UT Southwestern Medical CenterDallas, United StatesTaking people
- Velocity Clinical Research, DallasDallas, United StatesTaking people
- Teak Research Consults - DunwoodyDunwoody, United StatesTaking people
- Neighborhood Healthcare Institute of HealthEscondido, United StatesTaking people
- Ark Clinical Research, Fountain ValleyFountain Valley, United StatesTaking people
- Tribe Clinical Research LLCGreenville, United StatesTaking people
- East-West Medical Research InstituteHonolulu, United StatesTaking people
- MedStar Health Research Institute (MedStar Physician Based Research Network)Hyattsville, United StatesTaking people
- Care Access - Lake Charles (Bayou Pines)Lake Charles, United StatesTaking people
- AMR ClinicalLas Vegas, United StatesTaking people
- Teak Research ConsultsLawrenceville, United StatesTaking people
- BioMed Research & Medical CenterMiami, United StatesTaking people
- Monroe Biomedical ResearchMonroe, United StatesTaking people
- Adult Medicine of Lake County, Inc.Mt. Dora, United StatesTaking people
- Accellacare - Mt PleasantMt. Pleasant, United StatesTaking people
- AMR ClinicalNashville, United StatesTaking people
- AMR ClinicalNorfolk, United StatesTaking people
- Desert Oasis Healthcare Medical GroupPalm Springs, United StatesTaking people
- American Research Centers of FloridaPembroke Pines, United StatesTaking people
- AHF PensacolaPensacola, United StatesTaking people
- Care Access - QuincyQuincy, United StatesTaking people
- Rochester Clinical Research, LLCRochester, United StatesTaking people
- Peninsula Research AssociatesRolling Hills Estates, United StatesTaking people
- Care Access - SacramentoSacramento, United StatesTaking people
- IMA Clinical Research San AntonioSan Antonio, United StatesTaking people
- Southern California Clinical ResearchSanta Ana, United StatesTaking people
- Headlands Research - ScottsdaleScottsdale, United StatesTaking people
- IMA Clinical Research St. PetersburgSt. Petersburg, United StatesTaking people
- Clinical Research AtlantaStockbridge, United StatesTaking people
- Cotton O'Neil Clinical Research CenterTopeka, United StatesTaking people
- Arcturus Healthcare , PLC, Troy Internal Medicine Research DivisionTroy, United StatesTaking people
- MFA Clinical ResearchTuscaloosa, United StatesTaking people
- University Clinical Investigators, Inc.Tustin, United StatesTaking people
- Preferred Primary Care PhysiciansUniontown, United StatesTaking people
- IMA Clinical Research WarrenWarren Township, United StatesTaking people
- Chase Medical Research, LLCWaterbury, United StatesTaking people
- Iowa Diabetes and Endocrinology Research CenterWest Des Moines, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07321886EU 2025-523657-34-00
- Record updated
- 22 September 2026
- Original description
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.Read full original descriptionShow less
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, Without Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.
Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.
Inclusion: Have Body Mass Index (BMI) at screening of the following:; 30 kilogram per square meter (kg/m2) OR; 27 kg/m2 with at least one of the following weight-related health conditions at screening:; high blood pressure; dyslipidemia; obstructive sleep apnea, or; heart disease; Have a stable body weight (<5% body weight change) for 90 days prior to screening; Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have taken medications or alternative remedies intended for weight loss within 90 days of screening; Have type 1 diabetes or type 2 diabetes; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure.